EU transparency window "ajar, not open", say campaigners
This article was originally published in Scrip
The European Medicines Agency may have furthered its efforts towards greater openness by publishing the minutes of three of its main scientific committees, but some critics say that the "transparency window" is not yet fully open, partly because of last year's legal challenges to the agency's policy of providing access to documents.
You may also be interested in...
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.